Paul Harris, Ph.D.
Dr. Harris is an Associate Professor of Medical Science (in Medicine) at Columbia University School of Medicine in Manhattan. He received his undergraduate degree from the University of California, Berkeley in Biochemistry and Medical Biophysics, his Ph.D. in Cell Biology from Cornell University, and did Post Doctoral training in peptide chemistry at The Rockefeller University. He has been a faculty member at the health sciences campus of Columbia University since 1988. Dr’ Harris’ research efforts spanning 1990 to 2000 were instrumental in defining the structure of MHC bound peptides. Studies he co-authored provided the foundations for current vaccine design strategies.
Alessandro Sette, Ph.D.
Dr. Alessandro Sette is the Head of the La Jolla Institute of Immunology (LJI) Division of Vaccine Discovery. Dr. Sette’s laboratory is focused on the study of the specific structures (epitopes) that the immune system recognizes, and uses this knowledge for a variety of applications including research relevant to vaccines for cancer therapy.
He created, and has directed since the early 2000s, the Immune Epitope Database, a freely available, widely used bioinformatics resource. Dr. Sette has devoted more than 30 years to understanding and measuring immune responses, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. Dr. Sette has a doctorate in Biological Sciences from the University of Rome and was a postdoctoral fellow at the National Jewish Center in Denver, Colorado. In 1988, Dr. Sette joined Cytel Corp. and in 1997 founded Epimmune, where he was VP of Research and Chief Scientific Officer until 2002, when he joined LJI.
Tom Hodge, Ph.D.
Dr. Hodge received his Ph.D. in Immunology from East Tennessee State University College of Medicine in 1982, subsequently spending over 15 years at at CDC serving from 1993-2005 as Director of the Immunogenetics Laboratory, Division of HIV/AIDS Pathogenesis National Center HIV, STD and TB Laboratory Research. Prior to that he served from 1989-1993 as Section Chief, Molecular Immunology, Immunology Branch, Division of HIV/AIDS Pathogenesis, National Center for Infectious Diseases, Centers for Disease Control and Prevention. Dr. Hodge has over 40 peer reviewed publications, in addition to book chapters, patents, and US IND applications. Since leaving CDC, Dr. Hodge has been working with industry on on novel approaches for treating and preventing cancer and infectious diseases.
Tunde Otulana, M.D.
Dr. Otulana is Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals. At Mallinckrodt he provides global executive leadership across various medical functions for all company portfolios in the areas of autoimmune diseases, hospital critical care, acute care, specialty generics and specialty brand products. He overseers Global Medical Affairs, Global Pharmacovigilance & Drug Safety, Health Economics & Outcome Research (HEOR), Global Medical Information, and Scientific Communications. Dr. Otulana is a Clinical Professor of Medicine at the University of California, Davis School of Medicine. He has held multiple senior positions in the pharmaceutical industry and, from 1991-1997, was a Medical Reviewer / Medical Team Leader at the FDA. Dr. Otulana is advising Flow Pharma on various matters including clinical trial design and regulatory affairs.
Trung Nguyen, D.O.
Dr. Nguyen is a Clinical Assistant Professor, Department of Ob/Gyn Division of Gynecologic Oncology at the Stanford University School of Medicine. He is a GYN cancer surgeon having completed a Robert Wood Johnson Fellowship in Gynecologic Oncology. Dr. Nguyen is advising Flow Pharma on clinical trial design.
Jesse Wolf, Ph.D.
Dr. Wolf received his B.A. in Mathematics with Honors from Temple University in 1974.and his M.A. in Mathematics from UC Berkeley in 1978. Since 2007 he was at the CUNY Grad Center’s Doctoral Program in Mathematics, working in Applied Linear Algebra, receiving his Ph.D. in Mathematics in 2015 with Thesis: New Results on Randomized Matrix Computations. Applied Linear Algebra is the mathematical basis for neural networks used in Artificial Intelligence applications. Dr. Wolf is working with Flow Pharma’s bioinformatics team to develop novel, generalizable mathematical approaches to improve the efficiency of neural network calculations. Dr. Wolf is Adjunct Assistant Professor of Mathematics at BMCC, BCC. and Fordham University.
William Chao, Ph.D.
Dr. Chao is a structural biologist and Associate Professor, Faculty of Health Sciences, University of Macau, with special expertise in solving protein structures using x-ray crystallography. He received his Master’s degree in Molecular and Cellular Biochemistry, at St Peter’s College, University of Oxford, United Kingdom in 2007 and was subsequently awarded a Ph.D. from The Institute of Cancer Research, London, United Kingdom in 2011. He served as as Cancer Research UK Additional Quota Fellow at the London Research Institute / Francis Crick Institute, from 2012 – 2017. Dr, Chao is an author of numerous peer reviewed publications including a first authorship on a Nature paper describing a protein structure solution for the mitotic checkpoint complex — fundamental research describing mechanisms responsible for cell division. He is helping Flow Pharma scientists investigate structure / function relationships related to antigen presentation and vaccine design.
Nik is an AI data scientist and is head of machine learning at Ribbon in Manhattan. He is co-founder of Tetra and was featured in Forbes “30 under 30” in Enterprise Technology. Nik is a graduate of Phillips Exeter Academy and left Tufts to join Y-Combinator and found Tetra. He is helping Flow Pharma’s bioinformatics team.
Igor Gonda, Ph.D.
Dr. Gonda, served as the Chief Executive Officer and President at Aradigm Corporation 2006 – 2018. He has also served as the Chief Executive Officer and Managing Director of ACRUX Limited from December 2001 to August 10, 2006. From February 1992 to September 1995, Dr. Gonda served as a Senior Scientist and Group Leader at Genentech, Inc. with responsibility for all non-oral drug delivery. Dr. Gonda held academic positions at the University of Aston in Birmingham, UK and the University of Sydney, Australia. He also was on the founding Board of Directors of the International Pharmaceutical Aerosol Consortium of Regulatory Science. Dr. Gonda has a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, UK. Dr. Gonda is helping Flow Pharma develop inhalable formulations of FlowVax applications for infectious disease prevention.